Cancer treatment
Scientists in Hangzhou, People's Republic of China, have reported promising results from a study combining oncolytic adenovirus ZD55 with therapeutic gene IL-24, leading to enhanced antitumor effects in lung cancer. The researchers found that the combination of ZD55-IL-24 with chemotherapy agents, such as adriamycin (ADM) or cisplatin (DDP)
Cancer research
A significant challenge in the treatment of non-small cell lung cancer (NSCLC) arises when patients develop resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). According to recent research from the United States, approximately 70% of patients with NSCLC and EGFR mutations experience significant tumor regressions when treated
Cancer
China Sky One Medical, Inc., a leading pharmaceutical company, announced a strategic shift in its subsidiary Heilongjiang Tianlong Pharmaceutical Company's (Tianlong) research and development (R&D) focus from external use medicines to antibiotics and cardiac drugs. This move aims to capitalize on the growing demand for prescription
Cancer research
Researchers at Johns Hopkins University's Sidney Kimmel Comprehensive Cancer Center have made significant strides in the treatment of prostate cancer by combining low-dose cyclophosphamide with GM-CSF-secreting immunotherapy. The study, published in Expert Opinion On Investigational Drugs, demonstrates that this combination enhances antitumor immune effects, showing promise in breaking
Cancer
Researchers have developed novel fusion enzyme mutants, containing Herpes Simplex Virus-1 (HSV-1) thymidine kinase mutants and guanylate kinase, which significantly enhance prodrug sensitivity in vitro and in vivo. In a study published in Cancer Gene Therapy, the researchers generated two fusion constructs, MGMK/30 and MGMK/SR39, and evaluated their
Cancer research
A study conducted by S.R. Davis and colleagues at Monash University, in collaboration with the Journal of Clinical Endocrinology & Metabolism, aimed to investigate the effects of testosterone therapy on mammographic density in postmenopausal women not receiving estrogen/progestin therapy (EPT). The researchers used a randomized, double-blind, placebo-controlled trial
Cancer research
In a groundbreaking study published in Clinical Cancer Research, researchers from the University of Colorado developed a novel docetaxel conjugate that significantly enhances tumor inhibition when combined with antiangiogenic nanoparticles. The study demonstrated the efficacy of this combination therapy in lung cancer cells and xenografts in athymic nude mice, showcasing
Cancer treatment
Despite being informed about the risks and benefits of tamoxifen, a significant portion of high-risk women are unlikely to take the drug for breast cancer prevention. A study conducted by researchers at the University of Michigan Comprehensive Cancer Center found that only 6% of women said they were likely to
Cancer treatment
A study published in Cancer revealed that black women are less likely than white women to receive radiation therapy after a lumpectomy, a standard treatment for early stage breast cancer. The study, conducted by researchers at The University of Texas M. D. Anderson Cancer Center, examined Medicare records of over
Cancer research
Researchers in Chiba, Japan, have made significant findings regarding the transcriptional regulation of tumor suppressor p53 in response to glucose deprivation. The study, led by R. Okoshi and colleagues, discovered that cAMP-responsive element-binding protein (CREB) collaborates with AMP-activated protein kinase alpha (AMPKalpha) to regulate the transcription of p53. This interaction
Drugs
Genentech, Inc., a wholly owned member of the Roche Group, has announced positive results from a Phase II study of trastuzumab-DM1 (T-DM1) in women with advanced HER2-positive breast cancer. The study, known as TDM4374g, found that T-DM1 shrank tumors in 33 percent of women with metastatic HER2-positive breast cancer that
Drugs
Researchers at Kanazawa University have identified a previously unknown mechanism through which advanced prostate cancer (PCa) often relapses after androgen deprivation therapy (ADT). The study, published in Endocrine-related Cancer, reveals that prostate stromal cells and androgen-sensitive PCa LNCaP cells coordinately activate the androgen receptor through the synthesis of testosterone and
